Patient Advocacy Leaders and Drug Development Industry Network
Welcome to PALADIN, a first-of-its-kind consortium dedicated to transforming the pace of medicines development through optimizing patient advocacy group–industry collaboration.
We are a pre-competitive, disease-agnostic membership community working together to create consensus-based resources, guidelines and solutions that will transform how patient advocacy groups, pharmaceutical and biotechnology companies collaborate in the future.
“We’re excited to be building on the momentum that Vicky DiBiaso created as the Founding Executive Committee Chair in collaboration with patient advocacy groups (PAG) and pharmaceutical company members. Our consensus-driven approach to optimize PAG-Industry collaboration is delivering valuable and useful resources and insights to the clinical research enterprise.”
Len Valentino,
President, World Federation of Hemophilia USA,
PALADIN Executive Committee Co-Chair
Deirdre BeVard,
SVP, R&D Strategic Operations, CSL
PALADIN Executive Committee Co-Chair
Len Valentino,
President, World Federation of Hemophilia USA,
PALADIN Executive Committee Co-Chair
Deirdre BeVard,
SVP, R&D Strategic Operations, CSL
PALADIN Executive Committee Co-Chair
Our Why
The last decade has seen a proliferation in the number of investigational therapies, companies sponsoring active clinical trials, and with that, the number of collaborations between patient advocacy groups and biopharmaceutical companies. Collaborations aim to:
- Reach and recruit patients
- Help shape clinical development plans
- Ensure outcomes relevant to patient communities are reflected in drug development activity
- Support access to clinical trials for historically underserved communities
While well-intentioned, with few exceptions, collaborations between patient advocacy groups and industry have been limited in their effectiveness in making clinical research faster and more efficient.
PALADIN aims to standardize and structure these R&D-driven collaborations to optimize their impact.
Our Why
The last decade has seen a proliferation in the number of investigational therapies, companies sponsoring active clinical trials, and with that, the number of collaborations between patient advocacy groups and biopharmaceutical companies. Collaborations aim to:
– Reach and recruit patients
– Help shape clinical development plans
– Ensure outcomes relevant to patient communities are reflected in drug development activity
– Support access to clinical trials for historically underserved communities
While well-intentioned, with few exceptions, collaborations between patient advocacy groups and industry have been limited in their effectiveness in making clinical research faster and more efficient.
PALADIN aims to standardize and structure these R&D-driven collaborations to optimize their impact.
Have additional questions about our efforts?